SRSF7

Across TCGA pan-cancer cohorts, SRSF7 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SRSF7 data layer compared with 21 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher SRSF7 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SRSF7 expression acts as an unfavorable survival marker.

OV, BLCA, and READ are the cancer types where SRSF7 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	OS	Median	II,III,IV	0.021	0.844	<.001	36	view →
BLCA	OS	Median	All	0.069	0.688	<.001	18	view →
READ	DFS	Median	III,IV	0.255	0.757	.008	15	view →
LIHC	OS	Median	All	0.118	0.783	<.001	12	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

SRSF7–OV (OS)

Open the OV breakdown →